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Abstract
Background: Ribosomal protein S6 (rpS6), a component of the 40S ribosomal subunit, is involved in multiple
cellular bioactivities. However, its clinicopathological significance in non-small cell lung cancer (NSCLC) is poorly
understood.
Methods: Expressions of total rpS6 (t-rpS6) and phosphorylated rpS6 (Ser235/236, p-rpS6) were detected
immunohistochemically in 316 NSCLC tissues and 82 adjacent controls, followed by statistical evaluation of the
relationship between proteins expressions and patients’ survivals to identify their prognostic values. Cytological
experiments with overexpressing or silencing rpS6 by lentivirus in human bronchial epithelial (HBE) and NSCLC cell
lines were performed to explore potential mechanisms by which rpS6 affects the clinical development of NSCLC.
Additionally, specific RNA interference for Akt1, Akt2, Akt3, Akt inhibitor and subsequent cellular bioactivity tests
were employed as well to investigate the upstream regulation of rpS6.
Results: Positive rates of t-rpS6 and p-rpS6 were both significantly increased in NSCLC tissues, compared with controls
(82.91 vs 62.20 % for t-rpS6; 52.22 vs 21.95 % for p-rpS6; both P < 0.001). However, only hyperphosphorylation of rpS6,
expressed as either elevated p-rpS6 alone or the ratio of p-rpS6 to t-rpS6 (p-rpS6/t-rpS6) no less than 0.67, was greatly
associated with the unfavorable survival of NSCLC patients, especially for cases at stage I (all P < 0.001). The independent
adverse prognostic value of hyperphosphorylated rpS6 was confirmed by multivariate Cox regression analysis (hazard
ratios for elevated p-rpS6 alone and p-rpS6/t-rpS6 no less than 0.67 were 2.403, 4.311 respectively, both P < 0.001).
Overexpression or knockdown of rpS6, along with parallel alterations of p-rpS6, led to increased or decreased cells
proliferations respectively, which were dependent on redistributions of cell cycles (all P < 0.05). Cells migration
and invasion also changed with rpS6 interference (all P < 0.05). Furthermore, upstream overexpression or knockdown
of Akt2 or Akt2 phosphorylation inhibition, rather than Akt1 or Akt3, resulted in striking hyperphosphorylation or
dephosphorylation of mTOR, p70S6K and rpS6 (all P < 0.05), without any change in total proteins expressions. Further
tests showed markedly accompanied variation of cells proliferation, cell cycle distribution and invasion (all P < 0.05).
Conclusion: Hyperphosphorylation of rpS6, probably regulated by the Akt2/mTOR/p70S6K signaling pathway, is closely
relevant to the progression of NSCLC and it might be served as a promising therapeutic target for NSCLC treatment.
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Introduction
Lung cancer is widely considered as the leading cause of
cancer-related death, attributing more than one million
deaths per year around the world [1]. Non-small cell
lung cancer (NSCLC) accounted for the overwhelming
majority of lung cancer. Although much progress has
been made in the application of multidisciplinary treat-
ments for lung cancer, its 5-year survival rate only
slightly improved from 12.3 % in 1970s to 16.9 % in
2000s [1, 2]. Such a pessimistic situation is largely
ascribable to the underappreciated pathogenesis of lung
cancer. Up to recent, multitudinous studies have verified
the principal roles of various genetic abnormalities in the
development of lung cancer, which finally appear as the
dysfunctions of numerous proteins [3–5].
Ribosomes are important intracellular particles for pro-
tein synthesis with the composition of RNA and proteins.
Ribosomal protein S6 (rpS6) is one of the components of
the 40S ribosomal subunit. Although still not fully under-
stood, rpS6 has been functionally regarded as the stimula-
tor and/or inhibitor of certain types of mRNA translation,
as well as the regulator of cellular metabolisms, cells size,
survival and proliferation [6–8]. In most cases, phosphor-
ylation at the evolutionary conserved c-terminal serine
residues between Ser235 and Ser247 is believed to be the
activation of rpS6 and exerts important successive effects
[8–10]. The response of striatal to dopaminergic pharma-
cological manipulations, muscle fibers to the progressive
resistance exercise and even the myocardial cells with the
inflammatory stimulus were all related to the phosphoryl-
ation of rpS6 (p-rpS6) [10–13]. However, an opposite find-
ing that rpS6 could combine with the U3 nucleoprotein
complexes in nucleolus without the phosphorylation was
also reported [14], indicating the multiple functional
forms of rpS6.
Recently, much attention has been paid to the effects
of rpS6 in tumors. The over expression and activation
of rpS6 in lymphangioleiomyomatosis-associated angio-
myolipomas, pulmonary sclerosing hemangioma, dys-
plasia and squamous cell carcinoma of the oral cavity
and esophageal squamous cell carcinoma revealed the
influential roles of rpS6 either in benign or malignant
tumors [15–18]. Further explorations even showed the
positive rpS6-dependent cells viabilities in pancreatic
and breast cancers [19, 20]. Moreover, mTOR inhibi-
tors, which act as the dephosphorylator of rpS6, are
currently being evaluated as antiproliferative drugs in
several human malignancies, providing more functional
evidence for rpS6 [21, 22]. However, the slower prolif-
eration of mice embryonic cells with the increased
phosphorylation of rpS6 was observed as well to
contradict the traditional ideas [6].
Regarding the effects of rpS6 in NSCLC, it has been poorly
understood so far. In this study, we immunohistochemically
detected the expressions of total rpS6 (t-rpS6) and p-
rpS6 in NSCLC clinical tissues and analyzed their rele-
vance to the clinical characteristics respectively, estab-
lishing p-rpS6 as the activated form of rpS6 in NSCLC.
Then, the prognostic values of p-rpS6 in the whole co-
hort or early staged NSCLC patients were assessed with
the Cox regression model. To confirm the clinical find-
ings and investigate the potential mechanisms in which
the hyperphosphorylation of rpS6 promotes the devel-
opment of NSCLC, subsequent cytological experiments
with overexpressing or silencing t-rpS6 and p-rpS6
were carried out to observe the changes of cells bioac-
tivities in vitro. Moreover, upstream regulation mecha-
nisms of rpS6 were explored as well. Based on the fact
that the initiation and progression of NSCLC are
largely associated with the exceeding activities of Akt
family [23, 24], we attempted to explore whether it re-
lates the functions of rpS6. There are three isoforms
(Akt1, Akt2 and Akt3) in the Akt family, and each of
them holds distinguishing or even exactly opposite ef-
fects in different tumors [25]. Several studies have
found that rpS6 is phosphorylated by Akt1(Ser473)
approach in colorectal and bladder cancer cells [26, 27],
but there are also reports revealing the Akt-independent
phosphorylation of rpS6 [7, 28]. Expressions of the three
isoforms of Akt and the correlation between Akt and rpS6
phosphorylation, interfered by Akt lentivirus-mediated
knockdown or Akt inhibitor XII (Akti-2), were detected
separately to determine the principal regulator and signal-
ing pathway of rpS6 in NSCLC.
It is worth mentioning that in accordance with the
frequently positive phosphorylation residues of rpS6 in
tumors [20, 28, 29], we detected the phosphorylation of
Ser235/236 of rpS6 in the present study. Additionally,
as no specific phosphorylation inhibitor for rpS6 is
commercially available, the small hairpin RNA (shRNA)
lentivirus was employed to reduce both of t-tpS6 and
p-rpS6. Furthermore, the dephosphorylation of rpS6
was also obtained by Akt shRNA or phosphorylation
inhibitor.
Material and Methods
Patients and tissue samples
A total of 316 paraffin-embedded archived NSCLC tis-
sue samples and 82 adjacent normal controls were col-
lected from the Department of Pathology, West China
Hospital of Sichuan University, China (WCHSU). They
were removed from NSCLC patients who had received
potentially curative surgeries in WCHSU between 2003
and 2009 without any preoperative therapy. Clinical in-
formation was acquired by chart review; whereas the
survival data were gotten by telephone interviews, with a
mean postoperative follow-up period of 55.9 months.
The diagnosis of NSCLC histopathologic determination
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and differentiation evaluation were determined accord-
ing to the WHO classification. The International Union
against Cancer’s tumor-node-metastasis system was used
for pathological staging. All tumors were clinical staged
according to the tumor size/node/metastasis (TNM)
classification of the IASLC Lung Cancer Staging Project
(7th edition) [30]. Clinicopathological characteristics of
the 316 cases were summarized in Table 1, while the
demographic characteristics comparison of lung cancer
patients and controls were displayed in Additional file 1:
Table S1. Each patient had signed informed consent for
this study, and the ethical approval from the Ethics
Committee of Sichuan University was also obtained. All
methods were carried out in accordance with the
current guidelines and regulations.
Immunohistochemistry procedures
Immunohistochemical staining was performed for t-rpS6
and p-rpS6. The procedure was carried out by the stand-
ard approach according to the instructions of Envision
immunohistochemical staining kit (DAKO) and previous
report [31]. Briefly, each 4 um tissue slide was dried at
65 °C overnight. After the deparaffinization in a series of
xylene and dehydration with graded alcohols, 0.3 % fresh
hydrogen peroxide in methanol was used to block the
endogenous peroxidase. Inhibition for nonspecific bind-
ing sites was unnecessary with the Envision kit. Antigen
retrieval was performed with 1 mM EDTA buffer
(pH 8.0) at 95 °C for 90 min, followed by the free cool-
ing to room temperature. Sections were then incubated
with primary antibodies of t-rpS6 (CST, #2217, diluted
by 1:100) or p-rpS6 (Ser235/236, CST, #4858, diluted by
1:400) in humid chambers at 37 °C for overnight. The
next day, slides were washed by phosphate-buffered
saline (PBS, pH 7.2–7.4) for the incubation with the sec-
ondary antibody (EnVision™ System, K5027, Dako) for
30 min at room temperature. DAB (3-3’-Diaminobenzi-
dine Tetrahydrochloride) was applied for the color
development and then removed by distilled water rins-
ing. After the nucleus staining with hematoxylin, sec-
tions were evaluated under a light microscope. The
replacement of the primary antibodies with PBS was
used as negative controls; while the known colon carcin-
oma was considered as positive references.
Table 1 Relationship between clinicopathological characteristics, t-rpS6, p-rpS6 expressions and survival time (Log-rank)
Factors n (%) Median survival time (months) Log rank P
Gender Male 244 (77.22) 28 0.083
Female 72 (22.78) 32
Age/years <60 130 (41.14) 28 0.942
≥60 186 (58.86) 31
Histological type ADC 142 (44.94) 23 0.146
SCC 132 (41.77) 32
Others 42 (13.29) 22
Histological differentiation Poor 150 (47.47) 25 0.008*
Moderate/Well 166 (50.63) 32
Tumor size T1 + T2 167 (52.85) 36 <0.001*
T3 + T4 149 (47.15) 21
Lymph node invasion N0 138 (43.67) 37 <0.001*
N1 + N2 + N3 178 (56.33) 25
Distant metastasis M0 294 (93.04) 31 0.005*
M1 22 (6.96) 17
Stage I 87 (27.53) 56 <0.001*
II + III + IV 229 (72.47) 22
t-rpS6 P 262 (82.91) 28 0.230
N 54 (17.09) 35
p-rpS6 P 165 (52.22) 20 <0.001*
N 151 (47.78) 42
p-rpS6/t-rpS6 ≥0.67 188 (59.49) 12 <0.001*
<0.67 128 (40.51) 48
t-rpS6 total rpS6; p-rpS6 phosphorylation of rpS6; ADC adenocarcinoma; SCC squamous cell carcinoma; P positive expression; N negative expression
*: P < 0.05
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Evaluation of the immunohistochemical staining
The staining results were read separately by two experi-
enced pathologists without any clinical information. In
cases of disagreement, the third senior advisor was
turned to for a consensus. The yellow or brown staining
in cytoplasm for rpS6 and p-rpS6 was classified as posi-
tive, which was quantitatively defined as the previous
description [32]. Briefly speaking, proteins expressions
were assessed semiquantitatively in 10 randomly selected
fields under 200 magnification, with both of the immu-
nohistochemical intensity and positive fraction. Scores
for staining intensity was defined as follows: 0 for no ap-
preciable stain, 1 for barely detectable stains, 2 for read-
ily appreciable brown stains and 3 for dark brown stains.
At the same time, scores for the positive proportions
were: 0 for no tumor cell positively stained, 1 for less
than 10 % of tumor cells stained, 2 for 10 to 50 % of
tumor cells stained and 3 for more than half of cells
stained. Then the intensity and fractions scores were
multiplied to get the final results, from 0 to 9. For statis-
tical analysis, scores of 0 ~ 2 were defined as negative/
mild expressions, while 3 ~ 9 were positive (3 to 5: mod-
erate, 6 to 9: strong).
For a more accurate evaluating the activation of rpS6,
the ratio of p-rpS6 to t-rpS6 (p-rpS6/t-rpS6) was calcu-
lated, which were then divided into the high (≥0.67) and
low groups (<0.67).
Preparation of the overexpressed or small hairpin RNA
(shRNA) lentiviruses
Plasmids for rpS6 overexpression (oe) and shRNA silence
(sh) were purchased from the Genechem, Shanghai,
China. The overexpression construct for rpS6, Akt1, Akt2
and Akt3 were developed by subcloning PCR-amplified
full-length cDNA into the plasmid. Two sequences for
the rpS6-specific shRNA were 5’-GCAGAATATGC-
TAAACTTT-3’(sh1) and 5’-TGAACGCAAACTTCGT
ACT-3’ (sh2), and the shRNA for Akt1, Akt2 and Akt3
were 5’-GAGTTTGAGTACCTGAAGC-3’, 5’-GCACAG
GTTCTTCCTCAGC-3’ and 5’-TGGACAAAGATGGC-
CACATA-3’ respectively. Recombinant lentivirus pro-
duction (including negative controls without any
specific target, NC), cells transfection and stable-
transfected clones’ selection were conducted as the pre-
vious report [33].
Cell lines and cell culture
Human bronchial epithelial (HBE) cell line and NSCLC
cell lines, including SK-MES-1 for squamous carcinoma
and H1650 for adenocarcinoma, were purchased from
the American Type Culture Collection. The two NSCLC
cell lines were cultured in RPMI-1640 medium (Invitro-
gen, CA) supplemented with 10 % fetal bovine serum,
100 μg/ml penicillin and 100 μg/ml streptomycin; while
HBE were maintained in Keratinocyte-serum free medium
(Gibco, USA) with 0.05 mg/ml bovine pituitary extract,
5 ng/ml human recombinant EGF, 0.005 mg/ml insulin
and 500 ng/ml hydrocortisone according to the manufac-
ture. In the rpS6 activation mechanism experiment, Akt
inhibitor XII Isozyme-Selective Akti-2 (Merck, #124029-
2MG) was supplied in the cell culture of H1650 and SK-
MES-1 with 0.8 μmol/L, 3.2 μmol/L and 12.8 μmol/L sep-
arately, and treated for 24, 48, 72 and 96 h to determine
the optimum working condition. All cells were incubated
in a humidified aseptic condition at 37 °C with 5 % CO2.
Western blotting analysis
Proteins were extracted from cell lysates using protein
extraction kit (KeyGEN, China) and the concentration
was measured with the BCA Protein Assay Reagent
(Thermo, USA). Then proteins were subjected to the
10 % sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE; Bio-Rad, Hercules, CA) and elec-
trophoretically transferred to the dPVDF membrane
(Amersham Pharmacia Biotech, Piscataway, NJ). Specific
protein antibodies included anti-total rpS6 (CST, #2217),
anti-p-rpS6 (Ser235/236, CST, #4858), anti-p21Cip1 (CST,
#2947), anti-p27Kip1 (CST, #3688), anti-CDK2 (CST,
#2546), anti-CDK4 (CST, #12790), anti-Cyclin E (SAB,
#29030), anti-cyclin D1 (CST, #2978), anti-p-Rb (Ser780,
CST, #3590), anti-Paxillin (CST, #12065), anti-p-Paxillin
(Tyr118; CST, #2541), anti-vimentin (CST, #5741), anti-
N-cadherin (CST, #4061), anti-E-cadherin (CST, #3195),
anti-MMP-9 (CST, #13667), anti-MMP-2 (CST, # 5741),
anti-t-Akt1 (CST, #2967), anti-p-Akt1 (Ser473, CST, #
9018), anti-t-Akt2 (CST, #2964), anti-p-Akt2 (Ser474,
CST, #8599), anti-t-Akt3 (Biorbyt, #orb6787), anti-p-
Akt3 (Ser472, Biorbyt, #orb6790), anti-t-mTOR (CST,
#2983), anti-p-mTOR (Ser2448, CST, #5536), anti-t-
p70S6K (SAB, #21276) and anti-p-p70S6K (Ser424, SAB,
#21276) and anti-β-actin (CST, #4970) as an internal
control. All of the above antibodies were diluted by
1:1000, except for the anti-p-rpS6 by 1:2000. Protein
bands were analyzed with the Biometrics digitized image
software and recorded as integrated densities (ID). Ra-
tios of ID(each protein) to ID(β-actin) were the final results
for proteins levels [34].
Cell proliferation assays
Cell Counting Kit-8 (CCK-8, Dojindo, Japan) was ap-
plied for detecting cells proliferation, with the guidance
of the product instruction. Briefly, cells were seeded in
96-well plates repeated by six overnight for full adher-
ent. Then at the time points of 24, 48, 72, 96 and 120 h
after the initial culture, CCK-8 liquids were added to
react with cells for 1 to 2 h. Cells’ absorbance at
450 nm was measured with the microplate reader
(Thermo Scientific, USA).
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Cell cycle assays
The distribution of cell cycles was detected with propi-
dium iodide (PI; Sigma-Aldrich, Oakville, ON) staining
and flow cytometry analysis. Cells were harvested with
EDTA-free trypsin (Invitrogen, CA) and fixed by 70 %
cold ethanol over 12 h. Then PI, together with RNase A
and Triton X-100, was applied to stain the cells,
followed by the flow cytometry detection and analyzed
by the CXP software. Modifit LT 3.1 (USA).
Wound healing assays
The migration of HBE was evaluated by wound healing
assays. HBE cells with different treatment were cultured
in six-well plates in monolayer and manually scraped
with a 200 μl pipette tip. After 12 and 24 h of this
wound, images were taken to observe the closure of the
wounds. Six parallel lines were randomly drawn to
measure the average distance between the cells borders
and ratios of the distance at 12 and 24 h to the begin-
ning (0 h) were recorded as the final results [35].
Transwell assays
Invasion abilities of H1650 and SK-MES-1 cells were an-
alyzed by the transwell assays with 8 μm pore membrane
filters chamber kit (Corning, New York, USA) [36].
Briefly, cells were resuspended with serum-free medium
and collected within the top chamber. At the same time,
the bottom of wells were filled with complete medium
containing 10 % FBS. After the incubation over 24 h,
some invasive cells penetrated the polycarbonate mem-
branes and the less invasive ones did not, which could
be swabbed off by cotton bud. Then 4’6-diamidino-2-
phenylindole dye was used to stain the transmembraned
cells and they were manually counted under the fluores-
cence microscope. The average stained cells in 10 ran-
domly selected fields were recorded as the final results
for each chamber.
Statistical analysis
Chi-square test was applied to determine the association
between the t-rpS6, p-rpS6 expressions and clinicopath-
ological characteristics, and was also employed to com-
pare the demographic characteristics of NSCLC patients
and controls, which was a group analysis, rather than a
paired comparison. The survival of patients with differ-
ent clinical factors and t-rpS6, p-rpS6 expressions were
analyzed by Kaplan-Meier method and the difference
was compared with Log-rank test. Univariate Cox regres-
sion model was used to calculate the hazard ratio (HR)
and the multivariate analysis was performed to identify
the independent prognostic predictors. Results for the
cell proliferation, cell cycles distribution, wound healing,
transwell and Western blotting assays were all expressed
as mean ± standard deviation (SD) and compared by
one-way analysis of variance (ANOVA) with LSD test
between any two groups. All statistical analysis was car-
ried out using the software of SPSS 18.0 for Windows
(SPSS, Chicago, IL, USA). Differences were considered
statistically significant for P value less than 0.05.
Results
Both of t-rpS6 and p-rpS6 were highly expressed in
NSCLC
The expressions of t-rpS6 and p-rpS6 (Ser235/236)
were immunohistochemically detected in 316 NSCLC
tumor tissues and 82 adjacent normal controls. Demo-
graphic characteristics of the NSCLC patients and con-
trols were listed in Additional file 1: Table S1. There
was no significant difference in gender, age, smoking or
family history of tumors in the two groups (all P >
0.05). As shown in Fig. 1, both of t-rpS6 and p-rpS6
were abundantly accumulated in the cytoplasm of
NSCLC cells, but less frequently found in non-tumor
controls. Of the 316 tumor specimens, 262 cases
(82.91 %) were positively stained with t-rpS6 and 165
patients (52.22 %) revealed the p-rpS6 positive expres-
sion. In contrast, positive rates for t-rpS6 and p-rpS6
in normal tissues were 62.20 % (51/82) and 21.95 %
(18/82) respectively. The results suggested that both
of t-rpS6 and p-rpS6 were significantly elevated in
NSCLC (both P < 0.001).
Hyperphosphorylation of rpS6, but not the t-rpS6
overexpression, significantly associated with the
unfavorable clinical characteristics and survival of NSCLC
patients
The relationship between clinical characteristics and t-
rpS6, p-rpS6 expressions in the 316 cases of lung cancer
patients were summarized in Additional file 1: Table S2.
No remarkably different t-rpS6 expression was found in
variant clinical characteristics (all P > 0.05). However, the
hyperphosphorylation of rpS6 was significantly more
prevalent in larger tumor size (P < 0.001), lymph node
invasion (P < 0.001), distant metastasis (P = 0.015) and
advanced stage (P < 0.001) patients, whereas the associ-
ation with sex, age, tumor histological types or histo-
logical differentiation was weak (all P > 0.05).
Then, the postoperative survival for all patients was ana-
lyzed using the Kaplan-Meier method and the difference
in median survival time was compared with Log-rank test.
As shown in Table 1 and Additional file 2: Figure S1, poor
histological differentiation, enlarged tumors, presence of
regional lymph node invasion, distant metastasis and late
clinical stage were all greatly correlated with the bad out-
come in NSCLC patients (all P < 0.05). However, different
gender, age or tumor histological types showed slight vari-
ation (all P > 0.05).
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Regarding the proteins expressions, elevated t-rpS6 did
not predict poor prognosis. The positive t-rpS6 patients
held a 5-year survival rate of 11.1 % and the median sur-
vival time of 28 months, while the negative ones re-
vealed a 35-month median survival time with 14.9 %
cases surviving more than 5 years (Fig. 2a left and
Table 1; P > 0.05). However, the 5-year survival rate and
median survival time of patients with p-rpS6 overexpres-
sion were significantly lower than those with negative p-
rpS6 (Fig. 2a middle and Table 1; 3.0 % vs 26.5 %;
20 months vs 42 months, P < 0.001). Such results indi-
cated that the overactivation of rpS6, rather than its only
overexpression, greatly promoted the progress of
NSCLC. For further understanding the effects of rpS6
overactivation, the ratio of p-rpS6 to t-rpS6 (p-rpS6/t-
rpS6) was used to report its active extent. Patients with
a high p-rpS6/t-rpS6 no less than 0.67 were found to be
much more likely to have an adverse prognosis than
those with low p-rpS6/t-rpS6 less than 0.67 (Fig. 2a
right and Table 1; 2.1 vs 32.0 %; 12 months vs
48 months, P < 0.001).
For supervised analysis including clinical stages, we di-
vided the patients into early (I) and advanced stage (II +
III + IV) to explore the influence of rpS6 separately. Not
surprisingly, neither the early nor late staged patients
showed different survivals with the different t-rpS6
Fig. 1 Expression of t-rpS6 and p-rpS6 were both highly expressed in NSCLC tissues. Representative t-rpS6 and p-rpS6 immunohistochemical
stainings in squamous cell carcinoma squamous cell carcinoma (a) and adenocarcinoma (b) tissues showed their abundant accumulations in
the cytoplasm of tumor cells, which were divided into negative/mild, moderate and strong grade. However, their expressions in non-tumor lung
tissues (c) were negative or mild. Each low magnification (100 ×) were paired with a high magnification (400 ×) for clear observation. t-rpS6: total
rpS6; p-rpS6: phosphorylation of rpS6; ADC, adenocarcinoma; SCC, squamous cell carcinoma
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expression (Fig. 2b left and Fig. 2c left; P = 0.610 and
0.083, respectively). However, the high p-rpS6 led to
poor prognosis both in I stage (Fig. 2b middle; 8 months
vs 60 months, P < 0.001) and advanced patients (Fig. 2c
middle; 21 months vs 25 months, P = 0.004). Similar re-
sults were also found for the ratio of p-rpS6/t-rpS6 in
different staged patients (Fig. 2b right; 8 months vs
61 months, P < 0.001 for I stage; Fig. 2c right; 13 months
vs 45 months, P < 0.001 for late stage). It was also easy
to find out that rpS6 hyperphosphorylation, reported ei-
ther the positive expression of p-rpS6 or elevated ratio
of p-rpS6/t-rpS6, was a much more significant survival
factor for the early staged patients (I stage) than of the
late ones (II + III + IV stages) (Fig. 2b middle vs Fig. 2c
middle; and Fig. 2b right vs Fig. 2c right), though all of
them revealed statistical significance. These data sug-
gested that p-rpS6 was specifically more relevant to the
survival of early staged NSCLC patients.
In the further comparison, an elevated ratio of p-rpS6/
t-rpS6 seemed to be a bit more powerful than p-rpS6
alone in predicting the bad outcomes of NSCLC patients
(Fig. 2a right vs Fig. 2a middle; Fig. 2c right vs Fig. 2c
middle), despite the weak difference in I stage cases
(Fig. 2b right vs Fig. 2b middle).
Fig. 2 Kaplan-Meier survival curves for NSCLC patients with different rpS6 and p-rpS6 expressions. a The survival among the whole cohort
patients on the basis of t-rpS6, p-rpS6, p-rpS6/t-rpS6 showed the great significance of increased p-rpS6 and elevated p-rpS6/t-rpS6 in NSCLC
(both P < 0.001) and excluded the role of t-rpS6 overexpression (P > 0.05). b Survival cures indicated the important prognostic values of the
increased p-rpS6 and elevated p-rpS6/t-rpS6 in early staged NSCLC patients (both P < 0.001). c The hyperphosphorylation of rpS6 also predicted
the poor prognosis of advanced staged NSCLC patients (both P < 0.05), although the significance was not as remarkable as it in I stage cases.
t-rpS6: total rpS6; p-rpS6: phosphorylation of rpS6
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The above results indicated that the hyperphosphory-
lation of rpS6 was significantly associated with the un-
favorable prognosis of NSCLC patients, especially in the
early staged cases.
Hyperphosphorylation of rpS6 was an independent
adverse survival marker for NSCLC patients
Based on the findings above, prognostic values of each
clinical characteristics and protein expressions were
evaluated by the subsequent Cox regression analysis. As
shown in Table 2 with univariate assays, risks for bad
outcomes in the whole cohort substantially increased
with a poor histological differentiation, enlarged tumor
size, lymph node invasion, distant metastasis and ad-
vanced stage (hazard ratio, HR = 1.369, 2.154, 2.121,
1.835 and 4.143 respectively, all P < 0.05), which were
completely consistent with the previous Kaplan-Meier
survival curves. Moreover, patients with a high expres-
sion of p-rpS6 or rising p-rpS6/t-rpS6 were also at an
increased risk for short survival, especially for the ele-
vated p-rpS6/t-rpS6 (HR = 2.666 and 5.963 respectively
with both P < 0.001).
Further analysis in different clinical stages was per-
formed as well (Table 2). Only the hyperphosphorylation
of rpS6 significantly conferred unfavorable survivals,
both in early and advanced staged patients (HR = 5.916
and 12.304 for I stage; HR = 1.560 and 3.654 in late
stage; all P < 0.001). It was obvious that the significance
was much stronger in the early stage as well, especially
for the upraised p-rpS6/t-rpS6.
To determine the independent prognostic factors in
NSCLC, multivariate Cox regression models were
introduced for the statistically significant risk factors in
the univariate analysis (Table 3). Because of the similar
meaning of p-rpS6 and p-rpS6/t-rpS6, the multivariate
assays with one or two of them were performed separ-
ately. No matter including either p-rpS6 alone or p-
rpS6/t-rpS6 alone, the advanced clinical stage and
increased hyperphosphorylation of rpS6 were always in-
dependent adverse prognostic factors for NSCLC devel-
opment (all P < 0.05). However, with the two indexes of
p-rpS6 and p-rpS6/t-rpS6 combined at the same time,
only the increased p-rpS6/t-rpS6 and late clinical stage
were found to be the final independent predictors (both
P < 0.001). Interestingly, results for the p-rpS6/t-rpS6
alone and p-rpS6/t-rpS6 together with p-rpS6 were
exactly the same, indicating the dominant significance of
p-rpS6/t-rpS6 to p-rpS6.
Knockdown of t-rpS6, with the synchronous loss of
p-rpS6, inhibited the proliferation and invasion of NSCLC
cells by the upstream regulation of Akt2 signaling
pathway
To identify the potential molecular mechanism by
which rpS6 overactivation affects the clinical develop-
ment of NSCLC, cells biological activities with rpS6
lentivirus mediated interference were analyzed subse-
quently. Based on the weak expressions of t-rpS6 and
p-rpS6 in HBE but strong in the adenocarcinoma cell
line of H1650 and squamous cell carcinoma of SK-
MES-1 (Fig. 3a left), along with the similarly active
characteristics of H1650 and SK-MES-1 (Fig. 3a middle
and Fig. 3a right), rpS6 overexpressed or knockdown
plasmid was stalely transfected into HBE and H1650,
Table 2 Univariate analysis for the relationship between clinical characteristics, rpS6, p-rpS6 expressions and survival time in different
groups
Factors All patients Patients in I stage Patients in II+III+IV stage
HR 95 % CI P HR 95 % CI P HR 95 % CI P
Gender Male vs Female 1.288 0.961–1.726 0.091 2.021 0.900–4.539 0.088 1.110 0.810–1.522 0.516
Age/years < 60 vs ≥ 60 1.009 0.792–1.286 0.943 1.153 0.639–2.083 0.635 0.906 0.692–1.185 0.469
Histological type ADC vs SCC vs others 0.957 0.801–1.144 0.630 0.646 0.397–1.052 0.079 0.975 0.808–1.177 0.793
Histological differentiation Poor vs moderate/well 1.369 1.078–1.174 0.010* 1.604 0.882–2.915 0.122 1.058 0.815–1.374 0.672
Tumor size T3+T4 vs T1+T2 2.154 1.680–2.762 < 0.001* - - - 1.195 0.904–1.508 0.210
Lymph node invasion N1+N2+N3 vs N0 2.121 1.636–2.749 < 0.001* - - - 0.882 0.650–1.197 0.420
Distant metastasis M1 vs M0 1.835 1.181–2.851 0.007* - - - 1.401 0.898–2.185 0.137
Stage II+III+IV vs I 4.143 2.945–5.831 < 0.001* - - - - - -
t-rpS6 P vs N 1.206 0.882–1.647 0.241 0.791 0.407–1.536 0.489 1.430 0.989–2.069 0.580
p-rpS6 P vs N 2.666 2.056–3.456 < 0.001* 5.916 2.920–11.984 < 0.001* 1.560 1.165–2.089 0.003*
p-rpS6/t-rpS6 ≥ 0.67 vs < 0.67 5.963 4.437–8.016 < 0.001* 12.304 6.046–25.042 < 0.001* 3.654 2.641–5.056 < 0.001*
HR hazard ratio; CI confidence interval; t-rpS6 total rpS6; p-rpS6 phosphorylation of rpS6; ADC adenocarcinoma; SCC squamous cell carcinoma; P positive
expression; N negative expression
-: No calculation was carried out because of the absence of dependent factors. For example, tumor sizes in I stage patients were always in T1 or T2, indicating an
impossible comparison with T3 and T4 ones. Similarly, patients in I stage were always without any lymph node invasion or distant metastasis
*: P < 0.05
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SK-MES-1 individually (Fig. 3b). CCK-8 assay was per-
formed to assess the effects of rpS6 on cells proliferation.
Overexpression of t-rpS6, together with the corresponding
increase of p-rpS6 (Fig. 3b left), potently promoted the pro-
liferation of HBE cells by comparison with the negative
control vectors (NC) and blank HBE (Fig. 3c left; all P <
0.05 for the time points of 72, 96 and 120 h after the initial
cells seeding). The similar low proliferation of HBE and NC
groups excluded the possible off-target effect of the plasmid
vector. In contrast, t-rpS6 and p-rpS6 downregulation by
shRNA (Fig. 3b middle and Fig. 3b right) significantly atten-
uated H1650 and SK-MES-1 cells viability compared to the
controls, and the two specific shRNA sequences revealed
nearly the same effects (Fig. 3c middle and Fig. 3c right; all
P < 0.001 after 24 h since the cells seeding).
Considering that cell cycles are critical to regulating
cells proliferation and viability, the distribution of cell
cycles were then detected with PI staining and flow cy-
tometry assays. Results showed that overexpression of
rpS6 in HBE led to the remarkable reduction of G1-G0
cells, along with the increase of G2-M and S phase
(Fig. 3d left; all P < 0.05). Furthermore, sharp elevation
of p-Rb, cyclin D1, cyclin E, CDK2 and CDK4 were
found with the hyperphosphorylation of rpS6 from the
Western blotting assays, whereas p21 and p27, the
CDK inhibitors, were dramatically dropped (Fig. 3d
left; all P < 0.05). Conversely, rpS6 silence and dephos-
phorylation in H1650 and SK-MES-1 cell lines resulted
in the cells predominant aggregation in G0-G1 phase,
along with the reduced expressions of p-Rb, cyclin D1,
cyclin E, CDK2 and CDK4 but increase in p21 and p27
(Fig. 3d middle and Fig. 3d right; all P < 0.05). Repre-
sentative images of flow cytometry results of cell cycle dis-
tribution were placed in the Additional file 3: Figure S2. It
was clear that overactivation of rpS6 induced the G0-G1
escape to promote the cells proliferation; while loss of
rpS6 attenuated the cells viability by G0-G1 arrest.
This might be the one of the potential reasons of the
fast progressing of NSCLC patients with rpS6
hyperphosphorylation.
Given that migration and invasion are critical steps
for malignant tumors metastasis, wound healing assay
for HBE and transwell experiment for H1650 and SK-
MES-1 cell lines were employed to assess the ability of
cells migration. As shown in Fig. 4a, overexpression of
rpS6 and p-rpS6 prominently enhanced HBE migration.
To be specific, the area of the wound in rpS6 activated
HBE cells was significantly recovered after 12 h from
the gash; and it was almost completely closed after
24 h, which were evidently faster than the two controls
(all P < 0.05). Subsequent Western blotting assays for
the migration relative proteins showed the distinct in-
crease of N-cadherin, vimentin, MMP-2 and p-Paxillin,
but reduced E-cadherin in rpS6 hyperphosphorylated
HBE cells (Fig. 4a; all P < 0.05), though the changes of
Paxillin and MMP-9 were almost obscure (Fig. 4a; all
P > 0.05). Simultaneously, downregulation of t-rpS6 and
p-rpS6 in H1650 and SK-MES-1 led to the striking de-
crease of invasive cells and corresponding alterations of
related proteins (Fig. 4b; all P < 0.05). All together, these
data indicated that rpS6 is involved in the invasion and
migration capabilities of NSCLC cells, which might ex-
plain the clinical metastasis of NSCLC patients with
the abnormal activation of rpS6.
Moreover, regarding the upstream regulation of rpS6,
we found that the overexpression of Akt2 in HBE led to
dramatical phosphorylation of mTOR, p70S6K and rpS6
(Fig. 5a; all P < 0.05), but no decided change was ob-
served with the interference of Akt1 or Akt3 (Fig. 5a; all
P > 0.05). On the contrary, Akt2 depletion, rather than
Akt1 or Akt3, in the two NSCLC cell lines resulted in
pronounced dephosphorylation of mTOR, p70S6K and
rpS6 (Fig. 5b; all P < 0.05 for Akt2), indicating the key
role of Akt2 in rpS6 activation. Therefore, the specific
Akt inhibitor XII, which is a cell-permeable Akt1/2 in-
hibitor with improved solubility and Akt2 selectivity
(Akti-2), was used for further confirmation. In prelimin-
ary experiments, the phosphorylation of Akt2 was de-
tected after incubating with Akti-2 for 24, 48, 72 and 96 h
in gradient concentration of 0.8, 3.2 and 12.8 μmol/L. The
optimum inhibition was obtained at the point of 72 h. As
shown in Fig. 5b, in spite of full incubation for 72 h, nei-
ther p-Akt1 nor p-Akt3 was markedly reduced. However,
Akt2 were dramatically dephosphorylated in the concen-
tration of 12.8 μmol/L, leading the distinct reduce of p-
mTOR, p-p70S6K and p-rpS6. These data displayed the
essential regulation role of Akt2/ mTOR/p70S6K signaling
pathway in rpS6 activation in NSCLC.
Biological activities of cell lines with Akt2 overexpres-
sion or inhibition were evaluated as well. CCK-8 assays
Table 3 Multivariate analysis for the independent risk factors for
all patients (Multivariate Cox regression model with the method
of forward LR)
Factors HR 95 % CI P
Including p-rpS6 alone
Stage II + III + IV vs I 3.252 2.239–4.723 <0.001*
p-rpS6 P vs N 2.403 1.275–2.226 <0.001*
Including p-rpS6/rpS6 alone
Stage II + III + IV vs I 2.377 1.631–3.465 <0.001*
p-rpS6/rpS6 ≥0.67 vs < 0.67 4.311 3.154–5.894 <0.001*
Including both of p-rpS6 and p-rpS6/rpS6
Stage II + III + IV vs I 2.377 1.631–3.465 <0.001*
p-rpS6/rpS6 ≥0.67 vs < 0.67 4.311 3.154–5.894 <0.001*
HR hazard ratio; CI confidence interval; t-rpS6 total rpS6; p-rpS6
phosphorylation of rpS6; P positive expression; N negative expression
*: P < 0.05
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Fig. 3 (See legend on next page.)
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showed that the overactivation of Akt2 in HBE, accom-
panied by a parallel increase in p-rpS6 expression, but
not t-rpS6, had a strong proliferation-promotion effect
(Fig. 6a left; P < 0.05). However, Akt2 silence by lenti-
virus or dephosphorylation by Akti-2 markedly deterio-
rated the phosphorylation of rpS6 and suppressed the
proliferation of H1650 and SK-MES-1 cell lines (Fig. 6a
middle and Fig. 6 right; all P < 0.05). Separate variation
of p-rpS6, without any change of t-rpS6, significantly af-
fected the proliferation in all tested cell lines, providing
adequate evidence of the crucial employment of rpS6
phosphorylation in NSCLC, rather than its simple over-
expression. Analysis of the cell cycle profiles of asyn-
chronous growing cells also revealed the detectable cell
(See figure on previous page.)
Fig. 3 The regulation of rpS6 in cells proliferation. a The expressions of t-rpS6 and p-rpS6 in NSCLC cell lines (H1650 for the adenocarcinoma and
SK-MES-1 for squamous carcinoma) were also much higher than they were in human bronchial epithelial (HBE) cell lines, (left; all P < 0.05). CCK-8
and cell cycle assays showed the active proliferative ability of H1650 and SK-MES-1 (middle), and there were more H1650 and SK-MES-1 cells in
G2-M0 phase than HBE, but fewer in G2-M phase (right). b The expressions of t-rpS6 and p-rpS6 in HBE were both significantly increased with the
transfection of rpS6 overexpressed lentivirus (oe-rpS6; left) and dramatically decreased in H1650 and SK-MES-1 cell lines with rpS6 knockdown by
specific shRNA lentivirus (sh-rpS6; middle and right), separately compared with negative controls (NC). H1650 and SK-MES-1 were both transfected
by two different sequences targeting rpS6 (sh1-rpS6 and sh2-rpS6). All P < 0.05. c After 72 h for the oe-rpS6 transfection, cell proliferation in HBE
was significantly increased determined by CCK-8 assays (left). H1650 and SK-MES-1 proliferated much slower after 48 h for the sh-rpS6 transfection
(middle and right). All P < 0.05. d Overexpressions of t-rpS6 and p-rpS6 resulted in more HBE cells entering G2-M and S phase from G0-G1 phase,
along with the increase of p-Rb, Cyclin D1, Cyclin E, CDK2, CDK4 and decrease of p21Cip1, p27Kip1(left). In parallel, loss of t-rpS6 and p-rpS6 induced
H1650 and SK-MES-1 G0-G1 arrest and the corresponding expression alterations of cell cycles regulators (middle and right). All P < 0.05. The
percentage of cells in different phases cells were measured by flow cytometry. CCK-8 experiments were carried out in sextuplicate, and the remaining
tests were triplicate. Data are presented as mean ± SD. *: vs the corresponding blank control cell lines without any transfection (HBE, H1650 and SK-
MES-1 respectively), P < 0.05; #: vs the corresponding control cell lines with the negative control (NC) vectors transfection (HBE + oe-NC, H1650 + sh-NC,
SK-MES-1 + sh-NC, respectively), P < 0.05
Fig. 4 The regulation of rpS6 in cells migration and invasion. a Wound healing assays showed that the t-rpS6 and p-rpS6 overexpression in HBE
(HBE + oe-rpS6) caused a much faster the healing recover than the two controls (×200). The expressions of N-cadherin, vimentin, MMP-2 and
p-Paxillin were remarkably upregulated, but E-cadherin decreased significantly (All P < 0.05), in spite of the vague changes of Paxillin and MMP-9
(All P > 0.05). b Targeted knockdown of t-rpS6 and p-rpS6 (sh1-rpS6 and sh2-rpS6) notably inhibited the metastatic potentials of H1650 and
SK-MES-1 cells (×400). The expressions of relative proteins, including E-cadherin, N-cadherin, vimentin, MMP-9, MMP-2 and p-Paxillin changed
greatly as well (All P < 0.05). All experiments were carried out triplicate. Data are presented as mean ± SD. *: vs the corresponding blank control
cell lines without any transfection (HBE, H1650 and SK-MES-1 respectively), P < 0.05; #: vs the corresponding control cell lines with the negative
control (NC) vectors transfection (HBE + oe-NC, H1650 + sh-NC, SK-MES-1 + sh-NC, respectively), P < 0.05
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cycles redistributions by Akt2 overexpression or inhib-
ition, with the correlate p-rpS6 increasing or reducing
(Fig. 6b; all P < 0.05). Enhanced migration capability
with the high level of p-rpS6 was also observed in HBE
by wound healing assays (Fig. 6c left; all P < 0.05). In
contrast, the number of H1650 and SK-MES-1 cells
that were able to invade the pore membrane filter
chambers were reduced by nearly 70 % with p-rpS6 in-
hibition (Fig. 6c middle and Fig. 6c right; all P < 0.05).
The correlation between rpS6 phosphorylation and cell
lines activities, without any change of t-rpS6, might
provide full information for the fundamental role of
rpS6 hyperphosphorylation in NSCLC, rather than its
mere overexpression.
Discussion
It has been reported that rpS6 has diverse functions in cel-
lular metabolism as well as protein synthesis [6, 37, 38].
Exceptional expression or activation of rpS6 has been
found in multiple sclerosis [39], pancreatic cancer [40],
squamous cell carcinoma of the oral cavity [17], and
even the brain areas with acute ketamine-induced
neuroplasticity [41]. In this study, we demonstrate that
the expressions of t-rpS6 and p-rpS6 were both signifi-
cantly abundant in NSCLC tissues. However, only the
hyperphosphorylation of rpS6 strongly correlated with
the unfavorable clinicopathological characteristics of
NSCLC patients and the adverse prognosis. These re-
sults indicate that rpS6 is overactivated as phosphory-
lated, rather than merely overexpressed in NSCLC.
Consistent with our results, recent studies also re-
vealed the close relationship between the high level of
p-rpS6 and poor survival in esophagus squamous cell
carcinoma patients [18], pancreatic neuroendocrine
tumors [42] and sarcoma [43]. Clinical investigations
even showed the drug resistance with rpS6 hyperpho-
sphorylation in several kinds of malignant tumors [44, 45].
For a more accurate description of the activated degree of
rpS6, the ratio of p-rpS6 to t-rpS6 was introduced in our
study. As expected, both of the high expression of p-rpS6
alone and the increased ratio of p-rpS6/t-rpS6 were identi-
fied as the independent prognostic factors for NSCLC pa-
tients. However, further comparison revealed that p-rpS6/
t-rpS6 over 0.67 seemed to be a bit more powerful than
Fig. 5 The upstream regulation signaling pathway of rpS6. a Separate overexpression of Akt1, Akt2 and Akt3 in HBE cells showed that only Akt2
(oe-Akt2) led to marked hyperphosphorylation of mTOR, p70S6K and rpS6 (left; All P < 0.05); while Akt1 or Akt3 alteration resulted in no detectable
change of these proteins (left; All P > 0.05). In H1650 and SK-MES-1 cell lines, only the specific silence of Akt2 (sh-Akt2) caused significant loss
of p-mTOR, p-p70S6K and p-rpS6 (middle and right; All P < 0.05), and no notable alteration with the Akt1 and Akt3 knockdown were found
(sh-Akt1, sh-Akt3; middle and right; All P < 0.05). b H1650 and SK-MES-1 were treated with Akti-2 (Akt inhibitor XII) for 72 h in concentration of
0.8, 3.2 and 12.8 μM. Western blot assays revealed the strongest effect of 12.8 μM and the accompanied dephosphorylation of mTOR, p70S6K
and rpS6 (All P < 0.05). oe-Akt1: overexpression of Akt1; oe-NCa1: negative control for oe-Akt1; oe-Akt2: overexpression of oe-Akt2; oe-NCa2:
negative control for oe-Akt2; oe-Akt3: overexpression of oe-Akt3; oe-NCa3: negative control for oe-Akt3. sh-Akt1: knockdown for Akt1; sh-NCa1:
negative control for sh-Akt1; sh-Akt2: knockdown for Akt2; sh-NCa2: negative control for sh-Akt2; sh-Akt3: knockdown for Akt3; sh-NCa3:
negative control for sh-Akt3
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the p-rpS6 alone. The explanation is not far to seek, be-
cause p-rpS6/t-rpS6 as high as 0.67 was only referred to
the strong activation of rpS6. Such a combined and
quantitative measurement may provide a more accurate
method to predict the clinical outcomes of NSCLC pa-
tients. In addition, we also found that rpS6 hyperpho-
sphorylation conferred the ominous survival in patients
at stage I, which was rather more sensitive than it for
the whole or advanced cases; with much more decided
survival curves and far bigger HR values. This might be
one of the most significant highlights of our study ex-
tending the clinical role of p-rpS6 in early staged
NSCLC patients. Similar prognostic significance of p-
rpS6 was also found in I and II stage esophagus
squamous cell carcinoma subjects [18], substantiating
the important early predictive values of p-rpS6.
To clarify the potential mechanisms in which p-rpS6
exerts its effects in NSCLC, biological experiments
were subsequently conducted. As the specific phos-
phorylation inhibitor for rpS6 is commercially unavail-
able, shRNA was used alternatively, which led to the
reduced phosphorylation of rpS6 by decreasing the t-
rpS6 levels. We found that loss of t-rpS6, together with
p-rpS6 downregulation, greatly suppressed the NSCLC
cells viability by inducing G0-G1 cell cycles arrest,
along with the reduction of CDKs, cyclins and p-Rb.
However, rpS6 overexpression and activation in HBE
cells had the opposite effects. Similar to our data, the
Fig. 6 Alteration of cellular bioactivies with the changes of rpS6 phosphorylation from Akt2 interference or phosphorylation inhibition.
a CCK-8 assay revealed rpS6 hyphosphorylation from Akt2 overexpressing in HBE greatly promoted cells proliferation (left; P < 0.05), and
p-rpS6 reducing in H1650 and SK-MES-1 cells from Akt2 knockdown or phosphorylation inhibition markedly deteriorated cells proliferation
(middle and left; P < 0.05). b Influence of p-rpS6 on cell cycles in HBE and NSCLC cell lines (P < 0.05). c Wound-healing assay was performed
after rpS6 hyphosphorylation in HBE (left; P < 0.05), and cell migration assay was carried out after p-rpS6 reduce in H1650 and SK-MES-1 cell
lines (middle and left; P < 0.05). CCK-8 experiments were carried out in sextuplicate, and the remaining tests were triplicate. Data are presented as
mean ± SD. oe-Akt1: overexpression of Akt1; oe-NCa1: negative control for oe-Akt1; oe-Akt2: overexpression of oe-Akt2; oe-NCa2: negative control for
oe-Akt2; oe-Akt3: overexpression of oe-Akt3; oe-NCa3: negative control for oe-Akt3. sh-Akt1: knockdown for Akt1; sh-NCa1: negative control for sh-Akt1;
sh-Akt2: knockdown for Akt2; sh-NCa2: negative control for sh-Akt2; sh-Akt3: knockdown for Akt3; sh-NCa3: negative control for sh-Akt3. *: vs the
corresponding blank control cell lines without any transfection (HBE, H1650 and SK-MES-1 respectively), P < 0.05; #: vs the corresponding control cell
lines with the negative control (NC) vectors transfection (HBE + oe-NC, H1650 + sh-NC, SK-MES-1 + sh-NC, respectively), P < 0.05
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proliferation of several other kinds of cells, including
breast carcinoma, cervical carcinoma and even the nor-
mal embryonic kidney cell lines, is also dramatically
promoted by rpS6 phosphorylation [46]. Liver cells in
the late gestation rat revealed p-rpS6 dependent
growth as well [47]. Moreover, hepatic cells in the adult
mice with conditional deletion of the gene encoding
rpS6 failed to proliferate after partial hepatectomy [48].
These results support our findings and suggest that
rpS6 phosphorylation plays a crucial role in variant
cells proliferation. Regarding the relationship between
rpS6 and cell cycle regulation, it was firstly discovered
in the fertilized Xenopus eggs with Ras induction
nearly 10 years ago [49]. Following studies provided
more evidence that the depletion of rpS6 was able to
cause p53 induced cell cycles checkpoint impeding or
arrest [50, 51], suggesting the possible molecular mech-
anisms of rpS6 in cell cycles regulation. Recent re-
searches even ascribed the cell cycles regulation effects to
the phosphorylation at the site of Ser240/244 [18, 37, 52].
Although our study differed from the reports in the phos-
phorylated residues, the fact that rpS6-mediated cell via-
bility was largely related to the cells cycles redistributions
was almost believable. Continued investigations are re-
quired to determine whether the site of Ser235/236 is ex-
clusive phosphorylating target of rpS6 in NSCLC.
Wound healing assay and transwell experiment were
performed as well since the cells invasion and motility
are critical initiation for tumors spreading and progres-
sion. The migration of HBE cell lines distinctly amplified
under the induction of rpS6, and this was clearly paral-
leled by the expressions elevation of p-Paxillin, N-
cadherin, vimentin, MMP-2 and reduction of E-
cadherin, which are definite regulators of cells adhesion
and extracellular matrix degradation. Conversely, H1650
and SK-MES-1 cells migration were dramatically inhib-
ited after rpS6 knockdown. In line with our findings,
downregulation of p-rpS6 are also attenuated the cells
invasion in esophageal squamous cell carcinoma [18]
and renal angiomyolipoma [7]. MJ-56, a new novel anti-
metastasis drug, even showed the p-rpS6-mediated inva-
sion inhibition effects in colorectal cancer cells [53]. These
results imply that p-rpS6 might be importantly involved in
multiple cells invasion and its overexpression will prob-
ably facilitate the tumors aggressiveness to a large extent.
Moreover, how is rpS6 activated? Mounting evidence
has established the classical way of Akt1(Ser473) in
rpS6 activation [26, 27], but nevertheless the Akt-
independent phosphorylation of rpS6 was also reported
[7, 28]. In evaluating the crosstalk between rpS6 and
Akt pathway, we found that the expression of p-rpS6,
along with p-mTOR/p-p70S6K, changed markedly with
the interference of Akt2 by lentivirus or phosphoryl-
ation inhibitor; whereas neither Akt1/p-Akt1 nor Akt3/
p-Akt3 led to distinctive effect. The results were sup-
ported by the previous study that the decrease of Akt2
reduced the activation of rpS6 in neurons [54].
Responsive cell lines were then employed for bioac-
tivities testing in vitro. We found that even though
only the p-rpS6 level changed, without any alteration
in t-rpS6, cells proliferation, cell cycle distribution and
invasion varied in parallel as well. Combined with the
clinical findings that only the hyperphosphorylation of
rpS6 predicted the unfavorable survival in NSCLC pa-
tients, these data provide full evidence that rpS6 abnor-
mal activation as hyperphosphorylation is the key
molecule event in the development of NSCLC, and this
is probably Akt2 signaling pathway dependent.
Conclusions
In summary, our study demonstrates that rpS6 is exces-
sively activated in NSCLC as p-rpS6 and this dysregula-
tion is greatly relevant to the clinical progression of
NSCLC patients, independently leading an unfavorable
prognosis, especially in the early staged cases. Such clin-
ical significance could be confirmed by the cytological
bioactivities with the interference of rpS6 activation and
it might be derived from the abnormal upstream regula-
tion of Akt2/mTOR/p70S6K signaling pathway. Phos-
phorylation inhibition of rpS6 may be an effective
therapeutic strategy for the treatment of NSCLC.
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